Mammalian target of rapamycin (mTOR) inhibitor Archives

Tag: Mammalian target of rapamycin (mTOR) inhibitor

A substance that blocks a protein called mTOR, which helps control cell division. Blocking mTOR’s action may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Some mTOR inhibitors are used to treat cancer. In Neuroendocrine Cancer therapy, Everolimus (Afinitor) is an mTOR inhibitor

25 Aug 2024

By Ronny Allan

12 Comments

Chemo or not Chemo – that is the question

TreatmentAfinitor, Antineoplastic therapy, CAPecitabine TEMozolomide (CAPTEM)., Carboplatin, Chemotherapy, Cisplatin, Cytotoxic, Everolimus, Fluorouracil (5-FU), Hormone therapy, Lanreotide, Mammalian target of rapamycin (mTOR) inhibitor, mTOR inhibitor, Octreotide, Oxaliplatin (Eloxatin), Protein kinase inhibitor, Somatostatin analogues, Streptozotocin (Zanosar), Sunitinib (Sutent)

I often see certain drugs for the treatment of Neuroendocrine Tumours (NETs) described as "chemotherapy". Although since I wrote the first edition of this post in 2016, I don't see it as much today in 2024. Education is a wonderful thing! I think there must be some confusion with more modern drugs which are more targeted and work in a different way to Chemotherapy. According to Mayo Clinic: "In many ways, cytotoxic chemotherapy is "targeted" at specific molecules that regulate progression through the cell cycle; however, these targets are generally not specific for tumour cells. Because systemic cytotoxic chemotherapy targets…

22 Jun 2020

By Ronny Allan

0 Comments

Targeted Therapy for Neuroendocrine Cancer – Everolimus (Afinitor)

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Afinitor, Carcinoid syndrome, Clinical trial, Everolimus, Mammalian target of rapamycin (mTOR) inhibitor, Metastatic Neuroendocrine Cancer, Neuroendocrine cancer, Neuroendocrine neoplasm (NEN), Neuroendocrine tumour (NET), Pancreatic NET (PanNET), Targeted therapy

What is Everolimus (Afinitor)? Manufactured by Novartis, this is a targeted biological therapy or more accurately, a mammalian Target of Rapamycin (mTOR) inhibitor. It works by stopping some of the signals within cells that make them grow and divide. Everolimus stops a particular protein called mTOR from working properly. mTOR controls other proteins that trigger cancer cells to grow. So everolimus helps to stop the cancer growing or may slow it down. The drug is also approved for Renal Cell Carcinoma (RCC) and hormone-receptor-positive advanced Breast Cancer. The drug is administered in oral form (tablet). The recommended dose for AFINITOR®…

29 Jul 2019

By Ronny Allan

0 Comments

Surufatinib for Neuroendocrine Cancer

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Afinitor, Biliary tract cancer, Carcinoid tumour, Clinical trial, Colony stimulating factor-1 receptor (CSF-1R), Fibroblast growth factor receptor (FGFR), Incurable cancer, Mammalian target of rapamycin (mTOR) inhibitor, Metastatic Neuroendocrine Cancer, Neuroendocrine cancer, Neuroendocrine tumour (NET), Sulfatinib, Surufatinib, Tyrosine kinase inhibitor (TKI), Vascular endothelial growth factor (VEGF)

UPDATE 2nd May 2022.US FDA did not approve. Commentary from Healthcare New company Global Data. "On 2 May, the US Food and Drug Administration (FDA) rejected HUTCHMED’s new drug application (NDA) for its lead candidate, Sulanda (surufatinib), for the treatment of advanced neuroendocrine tumours (NETs). Issues pertaining to trial populations were raised in a complete response letter (CRL) and GlobalData expects this case to have wide implications for the whole field of oncology therapeutics.China-based HUTCHMED received approval for its multi-receptor tyrosine kinase inhibitor Sulanda in China for the treatment of pancreatic and extra-pancreatic NETs in June last year and December 2020,…